Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 172

2.

[Efficacy of atypical antipsychotics in depressive syndromes].

Quintin P, Thomas P.

Encephale. 2004 Nov-Dec;30(6):583-9. Review. French.

PMID:
15738862
3.

The other face of depression, reduced positive affect: the role of catecholamines in causation and cure.

Nutt D, Demyttenaere K, Janka Z, Aarre T, Bourin M, Canonico PL, Carrasco JL, Stahl S.

J Psychopharmacol. 2007 Jul;21(5):461-71. Epub 2006 Oct 18. Review.

PMID:
17050654
5.

SNRIs in the management of acute major depressive disorder.

Zajecka JM, Albano D.

J Clin Psychiatry. 2004;65 Suppl 17:11-8. Review.

6.

Augmentation strategies with serotonergic-noradrenergic combinations.

Nelson JC.

J Clin Psychiatry. 1998;59 Suppl 5:65-8; discussion 69. Review.

7.

Clinical evidence and potential neurobiological underpinnings of unresolved symptoms of depression.

Trivedi MH, Hollander E, Nutt D, Blier P.

J Clin Psychiatry. 2008 Feb;69(2):246-58. Review.

PMID:
18363453
8.

Antidepressant effectiveness in severe depression and melancholia.

Schatzberg AF.

J Clin Psychiatry. 1999;60 Suppl 4:14-21; discussion 22. Review.

9.

[Serotonin-noradrenaline reuptake inhibitors(SNRIs)].

Ishigooka J.

Nihon Rinsho. 2001 Aug;59(8):1523-9. Review. Japanese.

PMID:
11519152
10.

Is there a role for a pure noradrenergic drug in the treatment of depression?

Montgomery SA.

Eur Neuropsychopharmacol. 1997 Apr;7 Suppl 1:S3-9; discussion S71-3. Review.

PMID:
9169305
11.

Problems with currently available antidepressants.

Gumnick JF, Nemeroff CB.

J Clin Psychiatry. 2000;61 Suppl 10:5-15. Review.

12.

Mechanism of action of antidepressants.

Artigas F, Nutt DJ, Shelton R.

Psychopharmacol Bull. 2002 Summer;36 Suppl 2:123-32. Review.

PMID:
12490828
13.

Catecholaminergic strategies for the treatment of major depression.

Tremblay P, Blier P.

Curr Drug Targets. 2006 Feb;7(2):149-58. Review.

PMID:
16475956
14.

[Development of antituberculous drugs: current status and future prospects].

Tomioka H, Namba K.

Kekkaku. 2006 Dec;81(12):753-74. Review. Japanese.

PMID:
17240921
15.
16.

Reboxetine: a norepinephrine selective reuptake pump inhibitor.

Preskorn SH.

J Psychiatr Pract. 2004 Jan;10(1):57-63. Review. No abstract available.

PMID:
15334987
17.

The selective norepinephrine reuptake inhibitor antidepressant reboxetine: pharmacological and clinical profile.

Hajós M, Fleishaker JC, Filipiak-Reisner JK, Brown MT, Wong EH.

CNS Drug Rev. 2004 Spring;10(1):23-44. Review.

18.

Common pathways of depression and pain.

Delgado PL.

J Clin Psychiatry. 2004;65 Suppl 12:16-9. Review.

19.

New approaches to developing antidepressants by enhancing monoaminergic neurotransmission.

Bymaster FP, McNamara RK, Tran PV.

Expert Opin Investig Drugs. 2003 Apr;12(4):531-43. Review.

PMID:
12665410
20.

Emerging drugs for major depressive disorder.

Kennedy SH, Rizvi SJ.

Expert Opin Emerg Drugs. 2009 Sep;14(3):439-53. doi: 10.1517/14728210903107751. Review.

PMID:
19637989

Supplemental Content

Support Center